New Healthcare market report from Business Monitor International: "Qatar Pharmaceuticals & Healthcare Report Q3 2013"
Boston, MA -- (SBWIRE) -- 09/09/2013 -- Despite its favourable risk profile in relation to most of its regional neighbours, we continue to see Qatar as a relatively modest longer-term commercial proposition for research-based pharmaceutical manufacturers, on account of its modest population size of less than two million. Nevertheless, a growing non-communicable disease burden should ensure consumption continues to rise in volume terms, especially as Qatar continues to invest in healthcare and research infrastructures.
Headline Expenditure Projections
- Pharmaceuticals: QAR1.49bn (US$410mn) in 2012 to QAR1.68bn (US$462mn) in 2013; +12.9% in local currency and US dollar terms. Forecast broadly unchanged in relation to Q313.
- Healthcare: QAR14.02bn (US$3.85bn) in 2012 to QAR15.61bn (US$4.29bn) in 2013; +11.3% in both local currency and US dollar terms. Forecast broadly unchanged in relation to Q313, despite an upward revision of historical figures.
View Full Report Details and Table of Contents
Risk/Reward Rating: In BMI's Pharmaceutical Risk/Reward Rating (RRRs for the Middle East and Africa (MEA) region, Qatar now ranks seventh out of the 30 countries surveyed, having been fourth prior to the adjustment of our proprietary assessment tool. While Qatar's risks are particularly low in relation to the rest of the MEA region, its potential rewards are dampened by the small market size, although the country offers high per capita spending on pharmaceuticals. Despite the limited market size, Qatar's high level of urbanisation, rapid population growth and high prevalence levels of chronic lifestyle diseases create an environment in which there is strong potential for future market growth.
Key Trends And Developments
- According to local press reports from February 2013, Qatar-based Sidra Medical and Research Centre plans to recruit more than 4,500 healthcare professionals in the next two years. The medical facility will give employment preference to Arab medical personnel to encourage local skilled graduates. Sidra, which is expected to be inaugurated in 2014, will also provide the latest medical education and biomedical research opportunities to medical professionals. With an endowment of US$7.9bn from the Qatar Foundation, the facility will provide specialised care in obstetrics, gynaecology and paediatrics.
- In the same month, US company Aviir Inc signed an agreement with Partners & Partners (P&P), under which the latter will form the sole distributorship of Aviir's testing products and technologies in 19 Middle Eastern and North African countries, including Qatar. Through its affiliate, Qatar Heart Laboratory, P&P intends to launch, country-by-country, a network that will distribute and promote Aviir's tests.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Nigeria Pharmaceuticals & Healthcare Report Q4 2013
- Malaysia Pharmaceuticals & Healthcare Report Q3 2013
- Croatia Pharmaceuticals & Healthcare Report Q3 2013
- Kuwait Pharmaceuticals & Healthcare Report Q3 2013
- Latvia Pharmaceuticals & Healthcare Report Q4 2013
- Sweden Pharmaceuticals & Healthcare Report Q3 2013
- Australia Pharmaceuticals & Healthcare Report Q4 2013
- Lebanon Pharmaceuticals & Healthcare Report Q3 2013
- Jordan Pharmaceuticals & Healthcare Report Q3 2013
- Russia Pharmaceuticals & Healthcare Report Q3 2013